Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock option grants on August 20, 2026, covering an aggregate of 240,135 shares of common stock for twenty new non-executive employees. The options were granted under the company’s Amended and Restated 2021 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Each option has an exercise price of $8.99, equal to the closing price of Iovance’s common stock on the grant date. The awards vest over three years: one-third on the first anniversary of each employee’s start date, and the remaining two-thirds in eight quarterly installments over the following two years, subject to continued employment.

Positive

• 240,135-share inducement option grant to twenty new non-executive employees
• Exercise price set at market closing price of $8.99 on grant date
• Three-year vesting schedule with quarterly installments supports multi-year employee retention

Negative

• Potential shareholder dilution from up to 240,135 additional shares if options are exercised

Market Context

Historical event 1083528 recorded a 0.4% 24-hour reaction after a comparable grant announcement. Tha...

Analysis

Historical event 1083528 recorded a 0.4% 24-hour reaction after a comparable grant announcement. That precedent places this award in a recurring corporate-disclosure pattern; the active S-3ASR ATM registration remains a relevant capital-structure risk.

Key Figures

Grant Date: August 20, 2026 Shares Covered: 240,135 shares Recipients: 20 employees +4 more

7 metrics

Grant Date August 20, 2026 Inducement awards

Shares Covered 240,135 shares Aggregate stock options granted

Recipients 20 employees New, non-executive employees

Exercise Price $8.99 Closing price on the Date of Grant

Vesting Period Three years Each stock option

Initial Vesting One-third of shares First anniversary of employee start date

Quarterly Installments Eight installments Remaining shares over the next two years

Historical Context

5 past events · Latest: Aug 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 06	2Q26 earnings report	Positive	+43.1%	Record quarterly revenue and narrowed net loss accompanied the earnings announcement.
Jul 30	Earnings scheduling notice	Neutral	+2.9%	The company scheduled its second-quarter financial results report and corporate update.
Jul 17	Inducement stock grants	Neutral	+0.4%	Options covering 139,930 shares were granted to seventeen new employees.
Jun 19	Inducement stock grants	Neutral	+3.8%	Options covering 140,860 shares were granted to twenty-seven new employees.
Jun 03	Australian FDA approval	Positive	+15.6%	Amtagvi received conditional approval for advanced melanoma treatment in Australia.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

IOVA recorded positive 24-hour reactions after all five recent news events, including both prior inducement-grant announcements.

Key Terms

polyclonal tumor infiltrating lymphocyte, tumor infiltrating lymphocyte, inducement stock options, nasdaq listing rule 5635(c)(4)

4 terms

polyclonal tumor infiltrating lymphocyte medical

"novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies"

A polyclonal tumor infiltrating lymphocyte is a mix of different immune T cells taken from a patient’s tumor, grown in large numbers in the lab, and given back to attack cancer cells. It matters to investors because this type of personalized immunotherapy can drive clinical trial results, regulatory decisions, and potential commercial value for biotech companies developing cell‑based cancer treatments, much like recruiting and training an army made up of many different soldiers.

tumor infiltrating lymphocyte medical

"tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer"

Tumor-infiltrating lymphocyte (TIL) is an immune cell found inside a tumor that can recognize and attack cancer cells; researchers can extract and multiply these patient-derived cells to use as a personalized therapy. Investors watch TILs because therapies built from them offer a targeted, individualized approach—like retraining a patient’s own soldiers to fight a specific enemy—which can influence clinical trial outcomes, regulatory decisions, and the commercial value of biotech companies.

inducement stock options financial

"grant of inducement stock options covering an aggregate of 240,135 shares"

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 20, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 240,135 shares of Iovance’s common stock to twenty new, non-executive employees.

The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $8.99, the closing price of Iovance’s common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

About Iovance Biotherapeutics, Inc. 

Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi^® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit www.iovance.com.

Amtagvi^® and its accompanying design marks, Proleukin^®, Iovance^®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com
650-260-7120 ext. 150

FAQ

What inducement stock options did Iovance Biotherapeutics (IOVA) grant on August 20, 2026?

Iovance granted inducement stock options covering 240,135 shares of common stock to twenty new non-executive employees. According to Iovance, these awards were approved on August 20, 2026 under its Amended and Restated 2021 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of the new Iovance (IOVA) inducement stock options?

Each inducement stock option has an exercise price of $8.99 per share. According to Iovance, this price equals the closing price of its common stock on the August 20, 2026 grant date, aligning the awards with the market value at issuance.

How do the Iovance (IOVA) inducement stock options vest for new employees?

The options vest over a three-year period. According to Iovance, one-third of each grant vests on the first anniversary of the employee’s start date, with the remaining shares vesting in eight quarterly installments over the following two years, subject to continued employment.

How many employees received inducement stock options from Iovance (IOVA) in August 2026?

Twenty new non-executive employees received inducement stock options. According to Iovance, these grants cover an aggregate of 240,135 shares and were approved by the company’s compensation committee under its 2021 Inducement Plan on August 20, 2026.

Under which plan and Nasdaq rule were the August 2026 Iovance (IOVA) inducement options granted?

The options were granted under Iovance’s Amended and Restated 2021 Inducement Plan. According to Iovance, the plan allows equity awards to new employees to be made by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4) for inducement grants.